Unlock stock picks and a broker-level newsfeed that powers Wall Street.
XETRA - Delayed Quote EUR

Sartorius Stedim Biotech S.A. (56S1.DE)

Compare
181.15
0.00
(0.00%)
As of April 2 at 5:35:37 PM GMT+2. Market Open.
Loading Chart for 56S1.DE
  • Previous Close 181.15
  • Open 181.15
  • Bid 171.65 x --
  • Ask 172.25 x --
  • Day's Range 181.15 - 181.15
  • 52 Week Range 144.10 - 260.80
  • Volume 1
  • Avg. Volume 11
  • Market Cap (intraday) 17.624B
  • Beta (5Y Monthly) 0.98
  • PE Ratio (TTM) 100.08
  • EPS (TTM) 1.81
  • Earnings Date Apr 16, 2025
  • Forward Dividend & Yield 0.69 (0.38%)
  • Ex-Dividend Date Apr 2, 2025
  • 1y Target Est --

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

www.sartorius.com

9,901

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 56S1.DE

View More

Performance Overview: 56S1.DE

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

56S1.DE
2.92%
CAC 40 (^FCHI)
1.43%

1-Year Return

56S1.DE
29.31%
CAC 40 (^FCHI)
8.16%

3-Year Return

56S1.DE
52.64%
CAC 40 (^FCHI)
11.22%

5-Year Return

56S1.DE
303.48%
CAC 40 (^FCHI)
80.20%

Compare To: 56S1.DE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 56S1.DE

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    16.82B

  • Enterprise Value

    19.00B

  • Trailing P/E

    100.08

  • Forward P/E

    40.49

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.31

  • Price/Book (mrq)

    4.42

  • Enterprise Value/Revenue

    6.83

  • Enterprise Value/EBITDA

    28.33

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.30%

  • Return on Assets (ttm)

    3.10%

  • Return on Equity (ttm)

    5.33%

  • Revenue (ttm)

    2.78B

  • Net Income Avi to Common (ttm)

    175.1M

  • Diluted EPS (ttm)

    1.81

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    688.8M

  • Total Debt/Equity (mrq)

    71.31%

  • Levered Free Cash Flow (ttm)

    369.8M

Research Analysis: 56S1.DE

View More

Company Insights: 56S1.DE

Research Reports: 56S1.DE

View More

People Also Watch